课题基金 / 基金详情

GPI PHOSPHOLIPASE C OF T BRUCEI

GPI PHOSPHOLIPASE C OF T BRUCEI
布鲁氏菌的 GPI 磷脂酶 C
批准号:
2712290
负责人:
KOJO A. MENSA-WILMOT
金额:
$24.09万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
1993
资助国家:
美国
项目状态:
已结题
起止时间:
1993-07-01 至 2002-06-30

项目摘要

项目成果

KOJO A. MENSA-WILMOT的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
African trypanosomes sustain an infection in a mammalian host by antigenic variation, a process which involves the replacement of one variant surface glycoprotein (VSG) with a second (another) antigenically distinct VSG. Glycosylphosphatidylinositols (GPIs) are the anchors by which VSGs of varying polypeptide sequences are attached to the parasite plasma membrane. Without GPIs antigenic variation is likely to be foiled since VSG can no longer be attached to the plasma membrane. T. brucei expresses a phospholipase C (GPI-PLC) which cleaves GPIs with high efficiency. The enzyme colocalizes with GPI intermediates on the cytoplasmic side of cellular membranes, but surprisingly does not appear to cleave them. We are interested examining the regulatory mechanisms governing this apparent quiescence of GPI-PLC in vivo since the purified enzymes cleaves GPI intermediates in vitro. Our hypothesis is that constitutive activation of GPI-PLC in vivo will cause a GPI deficiency that will in turn lead to loss of cell-associated VSG. We have tested this hypothesis in Leishmania and T. cruzi and found it to be true: a GPI deficiency causes loss of the major GPI-anchored proteins gp63 and Ssp-4, respectively, in these parasites. A hopeful therapeutic approach against T. brucei which sidesteps the complication of antigenic variation involves a disruption of the mechanisms that keep the enzymatic activity of GPI-PLC quiescent in living cells. Because GPI-PLC cleaves the GPI anchor of VSG irrespective of the protein sequence (the source of the variation in antigens), the attachment of all VSGs to the plasma membrane can be prevented if GPL-PLC were constitutively activated in vivo to cleave GPI intermediates. Such a T. brucei cell line will be "coat-less". If introduced into a mammalian host, the prediction is that such a cell line will be eliminated by host immune response. Any VSGs that get expressed in GPI-deficient T. brucei will most likely be secreted, and be a source of a pool of VSGs for "live vaccination" if, and only if, the cell line were avirulent. In lieu of this long term aim, our specific aims are to (i) unravel the mechanisms which regulate GPI-PLC activity in vivo, and (ii) study enzymatic reaction mechanism of GPI-PLC.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Hit-to-lead optimization for sleeping sickness drug discovery
  • 批准号:
    9751174
  • 项目类别:
  • 资助金额:
    $69.08万
  • 财政年份:
    2016
  • 负责人:
    KOJO A. MENSA-WILMOT
  • 依托单位:
Hit-to-lead optimization for sleeping sickness drug discovery
  • 批准号:
    9078330
  • 项目类别:
  • 资助金额:
    $64.03万
  • 财政年份:
    2016
  • 负责人:
    KOJO A. MENSA-WILMOT
  • 依托单位:
Lead Optimization of Lapatinib Analogs for Human African Trypanosomiasis
  • 批准号:
    8904898
  • 项目类别:
  • 资助金额:
    $67.25万
  • 财政年份:
    2014
  • 负责人:
    KOJO A. MENSA-WILMOT
  • 依托单位:
Development of HTS assay and screening paradigm to discover new kinase inhibitors
国内基金
海外基金
基于cysteine代谢在内皮损伤中的作用探讨其在SARSCoV-2感染的致病机理及可能的治疗机制
  • 批准号:
    --
  • 项目类别:
    国际(地区)合作与交流项目
  • 资助金额:
    --
  • 批准年份:
    2020
  • 负责人:
    汪道文
  • 依托单位: